MPA
MCID: MCR088
MIFTS: 51

Microscopic Polyangiitis (MPA)

Categories: Bone diseases, Cardiovascular diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Microscopic Polyangiitis

MalaCards integrated aliases for Microscopic Polyangiitis:

Name: Microscopic Polyangiitis 53 59 37 17 33
Microscopic Polyarteritis 59 72
Micropolyangiitis 59
Mpa 59

Characteristics:

Orphanet epidemiological data:

59
microscopic polyangiitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Germany),1-9/1000000 (Norway),1-9/100000 (United Kingdom),1-9/100000 (Germany),1-9/100000 (Australia),1-9/100000 (Japan),1-9/100000 (Kuwait),1-9/1000000 (Canada),1-9/100000 (Greece),1-9/1000000 (Lithuania),1-9/100000 (Sweden); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

KEGG 37 H01658
ICD10 33 M31.7
MESH via Orphanet 45 D055953
ICD10 via Orphanet 34 M31.7
UMLS via Orphanet 73 C0343192
Orphanet 59 ORPHA727
UMLS 72 C2347126

Summaries for Microscopic Polyangiitis

KEGG : 37
Microscopic polyangiitis (MPA) is an idiopathic autoimmune disease characterized by systemic vasculitis. MPA predominantly affects small-calibre blood vessels and is associated with the presence of antineutrophil cytoplasmic autoantibodies (ANCA). The association with ANCAs originally defined the group of ANCA-associated vasculitides, comprising granulomatosis with polyangitis (GPA, formerly known as Wegener granulomatosis) [DS:H01655], microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly known as Churg-Strauss syndrome) [DS:H01468], which have different frequencies of ANCA-positivity. ANCA in MPA are predominantly directed against myeloperoxidase (MPO-ANCA) but may, in a minority of patients, be directed against proteinase 3 (PR3-ANCA). Not all patients, however, have ANCA. MPA is clinically characterized by small-vessel vasculitis primarily affecting the kidneys and the lungs but other organs may be involved as well. Renal involvement, which can be the only manifestation, is clinically apparent as rapidly progressive glomerulonephritis and histopathologically as pauci-immune necrotizing and crescentic glomerulonephritis. Diagnosis is mainly established by clinical manifestations, computed tomography (TC), ANCA antibody detection, and renal and pulmonary biopsy. The introduction of aggressive immunosuppressive treatment has substantially improved the prognosis. The standardized therapeutic regimen is based on cyclophosphamide and corticosteroids. Using this regimen, remission can be achieved in most of the patients. Rituximab may represent an important alternative to cyclophosphamide for patients who may not respond adequately to antimetabolite therapies.

MalaCards based summary : Microscopic Polyangiitis, also known as microscopic polyarteritis, is related to anca-associated vasculitis and vasculitis. An important gene associated with Microscopic Polyangiitis is MPO (Myeloperoxidase), and among its related pathways/superpathways are NF-kappaB Signaling and Toxoplasmosis. The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, lung and kidney, and related phenotypes are renal insufficiency and fever

NIH Rare Diseases : 53 Microscopic polyangiitis (MPA) is a disorder that causes blood vessel inflammation (vasculitis), which can lead to organ damage. The kidneys, lungs, nerves, skin, and joints are the most commonly affected areas of the body. MPA is diagnosed in people of all ages, all ethnicities, and both genders. The cause of this disorder is unknown.

Wikipedia : 75 Microscopic polyangiitis is an ill-defined autoimmune disease characterized by a systemic, pauci-immune,... more...

Related Diseases for Microscopic Polyangiitis

Diseases related to Microscopic Polyangiitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 404)
# Related Disease Score Top Affiliating Genes
1 anca-associated vasculitis 32.3 MPO HLA-DRB1 CTLA4
2 vasculitis 32.0 TNF MPO CX3CL1
3 churg-strauss syndrome 31.3 TNF MPO
4 granulomatosis with polyangiitis 31.1 MPO CTLA4
5 temporal arteritis 30.4 TNF HLA-DRB1
6 exanthem 30.4 TNF CTLA4
7 endocarditis 30.4 TNF FCGR2A
8 bronchitis 30.3 TNF MPO
9 hypersensitivity vasculitis 30.2 MPO HLA-DRB1
10 pleurisy 30.2 TNF MPO
11 membranous nephropathy 30.2 TNF MPO
12 granulocytopenia 30.1 TNF MPO
13 cholangitis 30.1 TNF HLA-DRB1
14 peritonitis 30.1 TNF MPO
15 autoimmune disease 30.1 TNF HLA-DRB1 CTLA4
16 central nervous system vasculitis 30.1 TNF HLA-DRB1
17 uveitis 30.0 TNF CTLA4
18 appendicitis 30.0 TNF MPO
19 graft-versus-host disease 30.0 TNF HLA-DRB1
20 mixed connective tissue disease 30.0 TNF HLA-DRB1
21 hematopoietic stem cell transplantation 30.0 TNF CTLA4
22 juvenile rheumatoid arthritis 29.9 TNF HLA-DRB1
23 takayasu arteritis 29.7 TNF HLA-DRB1 FCGR2A
24 cytomegalovirus infection 29.7 TNF CX3CL1
25 sarcoidosis 1 29.7 TNF HLA-DRB1
26 autoimmune hepatitis 29.6 HLA-DRB1 CTLA4
27 kawasaki disease 29.6 TNF FCGR2A
28 myasthenia gravis 29.6 TNF CTLA4
29 sclerosing cholangitis 29.6 TNF MPO HLA-DRB1
30 colitis 29.5 TNF MPO CTLA4
31 lupus erythematosus 29.4 TNF FCGR2A CTLA4
32 rheumatoid arthritis 29.2 TNF HLA-DRB1 CTLA4
33 rheumatic disease 29.2 TNF HLA-DRB1
34 rheumatoid vasculitis 29.0 TNF HLA-DRB1 CX3CL1
35 systemic lupus erythematosus 28.2 TNF MPO HLA-DRB1 FCGR2A CTLA4
36 glomerulonephritis 10.9
37 polyarteritis nodosa 10.7
38 crescentic glomerulonephritis 10.6
39 rapidly progressive glomerulonephritis 10.6
40 eosinophilic granulomatosis with polyangiitis 10.6
41 allergic angiitis 10.6
42 idiopathic interstitial pneumonia 10.5
43 pulmonary fibrosis 10.5
44 endometrial cancer 10.5
45 purpura 10.5
46 neuropathy 10.4
47 respiratory failure 10.4
48 end stage renal failure 10.4
49 lung disease 10.4
50 peripheral nervous system disease 10.4

Graphical network of the top 20 diseases related to Microscopic Polyangiitis:



Diseases related to Microscopic Polyangiitis

Symptoms & Phenotypes for Microscopic Polyangiitis

Human phenotypes related to Microscopic Polyangiitis:

59 32 (show all 38)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 59 32 hallmark (90%) Very frequent (99-80%) HP:0000083
2 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
3 skin rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0000988
4 erythema 59 32 hallmark (90%) Very frequent (99-80%) HP:0010783
5 hematuria 59 32 hallmark (90%) Very frequent (99-80%) HP:0000790
6 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
7 glomerulopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0100820
8 hemoptysis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002105
9 vasculitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002633
10 oliguria 59 32 hallmark (90%) Very frequent (99-80%) HP:0100520
11 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
12 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
13 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
14 skin ulcer 59 32 frequent (33%) Frequent (79-30%) HP:0200042
15 gastrointestinal hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0002239
16 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
17 venous thrombosis 59 32 frequent (33%) Frequent (79-30%) HP:0004936
18 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
19 subcutaneous hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0001933
20 gastrointestinal infarctions 59 32 frequent (33%) Frequent (79-30%) HP:0005244
21 peritonitis 59 32 frequent (33%) Frequent (79-30%) HP:0002586
22 arthritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001369
23 subcutaneous nodule 59 32 occasional (7.5%) Occasional (29-5%) HP:0001482
24 arrhythmia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011675
25 sinusitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000246
26 congestive heart failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001635
27 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
28 gangrene 59 32 occasional (7.5%) Occasional (29-5%) HP:0100758
29 pancreatitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001733
30 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
31 uveitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000554
32 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
33 cutis marmorata 59 32 occasional (7.5%) Occasional (29-5%) HP:0000965
34 episcleritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100534
35 abnormal retinal vascular morphology 32 occasional (7.5%) HP:0008046
36 peripheral neuropathy 59 Occasional (29-5%)
37 abnormality of the retinal vasculature 59 Occasional (29-5%)
38 increased inflammatory response 59 Very frequent (99-80%)

MGI Mouse Phenotypes related to Microscopic Polyangiitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.02 CTLA4 CX3CL1 FCGR2A MPO TNF

Drugs & Therapeutics for Microscopic Polyangiitis

Drugs for Microscopic Polyangiitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
2
leucovorin Approved Phase 4 58-05-9 143 6006
3
Mycophenolic acid Approved Phase 4 24280-93-1 446541
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
6
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
9
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
10 Dermatologic Agents Phase 4
11 Folic Acid Antagonists Phase 4
12 Nucleic Acid Synthesis Inhibitors Phase 4
13 Vitamin B9 Phase 4
14 Folate Phase 4
15 Vitamin B Complex Phase 4
16 Anti-Bacterial Agents Phase 4
17 Antitubercular Agents Phase 4
18 Antibiotics, Antitubercular Phase 4
19 Anti-Infective Agents Phase 4
20 Gastrointestinal Agents Phase 4
21 Antiemetics Phase 4
22 Neuroprotective Agents Phase 4
23 Prednisolone acetate Phase 4
24 Peripheral Nervous System Agents Phase 4
25 Methylprednisolone Acetate Phase 4
26 Autonomic Agents Phase 4
27 Tin Fluorides Phase 4
28
belimumab Approved Phase 3 356547-88-1 5957 10451420
29
rituximab Approved Phase 3 174722-31-7 10201696
30
Acetaminophen Approved Phase 3 103-90-2 1983
31
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
32
Clemastine Approved, Investigational Phase 3 15686-51-8 26987
33
Azathioprine Approved Phase 3 446-86-6 2265
34
Histamine Approved, Investigational Phase 3 51-45-6 774
35
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
36 Plasma Substitutes Phase 3
37 Antibodies, Antineutrophil Cytoplasmic Phase 3
38 glucocorticoids Phase 3
39 Anti-Inflammatory Agents Phase 3
40 Hormones Phase 3
41 Hormone Antagonists Phase 3
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
43 Antineoplastic Agents, Hormonal Phase 3
44 Antimetabolites Phase 3
45 Antimetabolites, Antineoplastic Phase 3
46 Neurotransmitter Agents Phase 3
47 Histamine Antagonists Phase 3
48 Histamine H1 Antagonists Phase 3
49
Histamine Phosphate Phase 3 51-74-1 65513
50 Immunoglobulin G Phase 3

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
2 Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy Unknown status NCT01405807 Phase 4 Alemtuzumab
3 Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
4 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
5 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
6 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Recruiting NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
7 Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial Recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
8 Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
9 Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
10 A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT01663623 Phase 3 Azathioprine
11 Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
12 Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial Completed NCT00987389 Phase 3 Glucocorticoids
13 Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
14 Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
15 Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial [Glucocorticoids] Completed NCT03919825 Phase 3 Glucocorticoids - Standard Dose;Glucocorticoids - Reduced Dose
16 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
17 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
18 Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study Recruiting NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
19 Evaluating Favorable, Immunological Effects of Rituximab With Cyclophosphamide Compared to Rituximab Alone in AAV Patients Recruiting NCT03942887 Phase 3 Rituximab;endoxan;Methylprednisolone;Prednisolone
20 Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial Active, not recruiting NCT02433522 Phase 3 rituximab;Placebo
21 An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis Active, not recruiting NCT01697267 Phase 3 Azathioprine
22 Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Not yet recruiting NCT03920722 Phase 3 Rituximab;placebo
23 Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener’s Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
24 Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
25 Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
26 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial. Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
27 A Phase IIA, International, Multicenter, Open-label, Uncontrolled Study to Evaluate The Safety And Pharmacokinetics of 4 × 375 mg/m2 Intravenous Rituximab in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed NCT01750697 Phase 2 Rituximab
28 Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
29 An Open Trial of the Efficacy of Glucocorticoids and Methotrexate (MTX) in the Treatment of Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
30 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Efficacy and Safety Study of IFX-1 in Add-On to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Recruiting NCT03712345 Phase 2 IFX-1;IFX-1;Placebo
31 A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Recruiting NCT03895801 Phase 2 IFX-1;Placebo-IFX-1;Glucocorticoid (GC);Placebo-Glucocorticoid (Placebo-GC)
32 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
33 A Pilot Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Pulmonary Fibrosis With Anti-myeloperoxydase (MPO) Antibodies or With Anti-MPO Associated Vasculitis." Recruiting NCT03385668 Phase 2 Pirfenidone
34 A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
35 A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis Withdrawn NCT01598857 Phase 2 Blisibimod;Placebo
36 A Pilot Study of Mycophenolate Mofetil (MMF) in Patients With p-ANCA Microscopic Polyangiitis and Mild to Moderate Renal Dysfunction. Completed NCT00405860 Phase 1 CellCept (mycophenolate mofetil)
37 High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
38 Cohort Study of Chinese Patients With Pulmonary Vasculitis Unknown status NCT02126098
39 A Qualitative Study Using Interviews With Patients Who Have Anti-neutrophil Cytoplasm Antibody (ANCA) Associated Vasculitis, to Develop a Patient Reported Outcome (PRO) Measure Unknown status NCT01729624
40 ACR/EULAR Endorsed Study to Develop New Diagnostic and Classification Criteria for Primary Systemic Vasculitis Unknown status NCT01066208
41 Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies Completed NCT00307593 Infliximab;Rituximab
42 Prospective, Observational Safety Study of Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Treated With Rituximab Completed NCT01613599 Rituximab
43 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
44 Educational Needs of Patients With Systemic Vasculitis- an International Survey Completed NCT02190929
45 Illness Perception, Fatigue, and Function in Systemic Vasculitis (The VCRC Vasculitis Perception (VIP) Study) Completed NCT02190916
46 The Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
47 Impact of Vasculitis on Employment and Income. An Online Survey of Participants in the VCRC Patient Contact Registry Completed NCT02476292
48 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
49 Determining Disease Activity Biomarkers in Individuals With Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis Recruiting NCT00315393
50 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326

Search NIH Clinical Center for Microscopic Polyangiitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Rituximab

Genetic Tests for Microscopic Polyangiitis

Anatomical Context for Microscopic Polyangiitis

MalaCards organs/tissues related to Microscopic Polyangiitis:

41
Neutrophil, Lung, Kidney, Skin, Testes, Endothelial, Bone

Publications for Microscopic Polyangiitis

Articles related to Microscopic Polyangiitis:

(show top 50) (show all 1733)
# Title Authors PMID Year
1
Update on the Management of Respiratory Manifestations of the Antineutrophil Cytoplasmic Antibodies-Associated Vasculitides. 38
31376892 2019
2
Significant association between clinical characteristics and immuno-phenotypes in patients with ANCA-associated vasculitis. 38
31377799 2019
3
Epidemiology and clinical features of childhood-onset anti-neutrophil cytoplasmic antibody-associated vasculitis: a clinicopathological analysis. 38
31076873 2019
4
Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Is There Still a Role for Cyclophosphamide? 38
31277751 2019
5
Microscopic polyangiitis masquerading as a pancreatic neoplasm with multiple lung metastases. 38
31434674 2019
6
[ANCA-associated vasculitides : State of the art]. 38
31028473 2019
7
Evaluation of 12 different assays for detecting ANCA in Chinese patients with GPA and MPA: a multicenter study in China. 38
31414304 2019
8
Impact of treatment on damage and hospitalization in elderly patients with microscopic polyangiitis and granulomatosis with polyangiitis. 38
31308208 2019
9
Incidence and prevalence of granulomatosis with polyangiitis and microscopic polyangiitis in health management organization in Argentina: a 15-year study. 38
30746579 2019
10
ANCA-Associated Vasculitis: Core Curriculum 2020. 38
31358311 2019
11
Clinical features and prognosis of microscopic polyangiitis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis. 38
31013398 2019
12
Reactivation of latent cytomegalovirus infection in patients with rheumatologic disease: a case-control study. 38
31076831 2019
13
The presence of anti-neutrophil extracellular trap antibody in patients with microscopic polyangiitis. 38
30897615 2019
14
Plasma Exchange Therapy to Reduce Mortality in Japanese Patients With Diffuse Alveolar Hemorrhage and Microscopic Polyangiitis. 38
31233282 2019
15
Nonatherosclerotic Abdominal Vasculopathies. 38
31200053 2019
16
Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist. 38
31242923 2019
17
Fibrosis-4 index at diagnosis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis. 38
31196158 2019
18
Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study. 38
30737591 2019
19
Comparison of Radiological and Histological Findings of Lung Parenchyma in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. 38
31016907 2019
20
Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis. 38
30613065 2019
21
Targeted immunotherapy strategies in ANCA-associated vasculitis. 38
30201478 2019
22
Systematic review and meta-analysis of clinical significance of autoantibodies for idiopathic pulmonary fibrosis. 38
31147365 2019
23
Microscopic polyangiitis associated with subarachnoid hemorrhage. 38
31191777 2019
24
Isolated cilioretinal artery occlusion secondary to perinuclear antineutrophil cytoplasmic antibody vasculitis. 38
30947529 2019
25
Microscopic polyangiitis associated with thymic tumor: a case report and review of the literature. 38
30961527 2019
26
European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides - the SHARE initiative. 38
30535249 2019
27
Incidence and risk factors of new-onset hypertrophic pachymeningitis in patients with anti-neutrophil antibody-associated vasculitis: using logistic regression and classification tree analysis. 38
30483978 2019
28
No overlap between IgG4-related disease and microscopic polyangiitis and granulomatosis with polyangiitis despite elevated serum IgG4 at diagnosis: a retrospective monocentric study. 38
30552533 2019
29
Association between preexisting lung involvements and the risk of diffuse alveolar hemorrhage in patients with microscopic polyangiitis: A multi-center retrospective cohort study. 38
30929541 2019
30
Chest High-Resolution CT Findings of Microscopic Polyangiitis: A Japanese First Nationwide Prospective Cohort Study. 38
30973774 2019
31
An atypical pneumonia. 38
30766683 2019
32
Recognizing Central Nervous System Involvement as a Progressive Feature of Microscopic Polyangiitis: A Diagnostic Dilemma. 38
30986393 2019
33
Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. 38
30887055 2019
34
Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis. 38
31162031 2019
35
Kaposi sarcoma development following microscopic polyangiitis treatment. 38
31031393 2019
36
Clinical Effect of Alpha-1 Antitrypsin Deficiency in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Results from a French Retrospective Monocentric Cohort. 38
30824651 2019
37
Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. 38
30805643 2019
38
Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. 38
29718465 2019
39
Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. 38
30542206 2019
40
Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: A retrospective analysis of 455 patients from a single center in China. 38
29887327 2019
41
Clinical role of albumin to globulin ratio in microscopic polyangiitis: a retrospective monocentric study. 38
30218289 2019
42
Microscopic polyangiitis and interstitial lung disease. 38
30001894 2019
43
Imaging in small and medium vessel vasculitis. 38
30698353 2019
44
Impact of caring for someone with a rare rheumatic condition, views from patients and informal carers-the need for cat-like vigilance. 38
31431991 2019
45
Is granulomatosis with polyangiitis in Asia different from the West? 38
30338654 2019
46
Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. 38
31245051 2019
47
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Korea: A Narrative Review. 38
30554486 2019
48
Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation. 38
31216309 2019
49
Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis. 38
30886997 2019
50
Systemic Lupus Erythematosus (SLE) and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis (AAV) Overlap Syndrome: Case Report and Review of the Literature. 38
30723567 2019

Variations for Microscopic Polyangiitis

Expression for Microscopic Polyangiitis

Search GEO for disease gene expression data for Microscopic Polyangiitis.

Pathways for Microscopic Polyangiitis

GO Terms for Microscopic Polyangiitis

Cellular components related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.8 TNF HLA-DRB1 CTLA4

Biological processes related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of inflammatory response GO:0050729 9.46 TNF CX3CL1
2 positive regulation of smooth muscle cell proliferation GO:0048661 9.43 TNF CX3CL1
3 negative regulation of T cell proliferation GO:0042130 9.4 HLA-DRB1 CTLA4
4 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.37 TNF CX3CL1
5 negative regulation of interleukin-6 production GO:0032715 9.32 TNF CX3CL1
6 microglial cell activation GO:0001774 9.26 TNF CX3CL1
7 negative regulation of growth of symbiont in host GO:0044130 9.16 TNF MPO
8 defense response GO:0006952 9.13 TNF MPO CX3CL1
9 immune response GO:0006955 8.92 TNF HLA-DRB1 CX3CL1 CTLA4

Sources for Microscopic Polyangiitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....